Trial Profile
A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Linsitinib (Primary)
- Indications Cancer; Cervical cancer; Colon cancer; Colorectal cancer; Oesophageal cancer; Ovarian cancer; Rectal cancer
- Focus Adverse reactions; Registrational
- 18 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jan 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2015 as reported by ClinicalTrials.gov.